The treatment of symptomatic benign breast disease with danazol

George Ramsey‐Stewart, G Ramsey-Stewart
The Australian & New Zealand journal of obstetrics & gynaecology · 1988 · vol. 28(4) , pp. 299–304 · doi:10.1111/j.1479-828x.1988.tb01686.x · PMID:3074777 · W2072631596
RCT OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Danazol treatment of 80 women with severe cyclical symptomatic benign mammary dysplasia showed significant improvement in breast pain, tenderness, and nodularity compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A prospective randomized double blind trial, using danazol in a dose of 200 mg twice a day, was carried out on 80 women presenting with severe cyclical symptomatic benign mammary dysplasia. Standardized scores for 4 parameters of disease severity (breast pain, breast tenderness, breast nodularity and breast cysts) were defined and measured monthly on all patients admitted to the trial. Using nonparametric statistical analysis, significant improvement in breast pain, tenderness and nodularity, was found in both the double blind and crossover arms of the trial. An insufficient number of patients presented with breast cysts to draw any conclusions regarding the efficacy of danazol on cysts. Six months of treatment may produce a more sustained response, than 3 months of treatment. Danazol appears to be efficacious in managing patients with severe breast symptoms due to benign disease.

My notes (saved in your browser only)

MeSH descriptors

Danazol Fibrocystic Breast Disease Pain Pregnadienes Clinical Trials as Topic Danazol Double-Blind Method Female Fibrocystic Breast Disease Humans Pain Pregnadienes Prospective Studies Random Allocation Time Factors

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (15)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-11T06:10:27.824888+00:00
pubmed
last seen: 2026-10-08T21:23:58.330360+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK